Precision Biosciences Inc (DTIL) — SEC Filings
Precision Biosciences Inc (DTIL) — 43 SEC filings. Latest: ARS (Apr 8, 2026). Includes 21 8-K, 5 10-Q, 5 SC 13G/A.
View Precision Biosciences Inc on SEC EDGAR
Overview
Precision Biosciences Inc (DTIL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 8, 2026: Precision BioSciences Inc. filed an Annual Report to Security Holders (ARS) on April 8, 2026, for the period ending December 31, 2025. The filing, with SEC Accession No. 0001140361-26-013759, provides a comprehensive update on the company's activities and financial standing for the fiscal year. The
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Precision Biosciences Inc is neutral.
Filing Type Overview
Precision Biosciences Inc (DTIL) has filed 1 ARS, 2 DEFA14A, 21 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 5 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of DTIL's 26 recent filings, 2 were flagged as high-risk, 16 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $60K |
| Net Income | ($65.857M) |
| EPS | ($1.84) |
| Debt-to-Equity | 4.62 |
| Cash Position | $44.870M |
| Operating Margin | -107.75% |
| Total Assets | $93.510M |
| Total Debt | $76.876M |
Key Executives
- Durham
- Dr. Michael A. Caligiuri
- Dr. Sarah E. Michaels
Industry Context
Precision BioSciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on gene editing technologies. The industry is characterized by long development cycles, significant R&D investment, and a high rate of failure. Success hinges on technological innovation, intellectual property protection, and the ability to secure substantial funding for clinical trials and commercialization.
Top Tags
divestiture (5) · strategic-shift (5) · sec-filing (4) · Biotechnology (4) · corporate-governance (4) · financing (4) · biotechnology (3) · 10-Q (3) · Precision BioSciences (3) · biotech (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-38841 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 20-4206017 | Company's tax identification number. |
| Revenue | $60K | 99.9% decrease from $68.058M in 2024 for the nine months ended September 30, 2025 |
| Net Loss | ($65.857M) | Compared to $24.912M net income in 2024, a significant swing to loss |
| Cash and Cash Equivalents | $44.870M | 47.8% decrease from $85.899M at December 31, 2024 |
| Net Loss Per Share (Basic) | ($1.84) | For the three months ended September 30, 2025, compared to ($2.25) in 2024 |
| Common Stock Shares Outstanding | 12,109,680 | As of September 30, 2025, up from 8,229,730 at December 31, 2024, indicating dilution |
| Total Operating Expenses | $64.716M | Decreased by 6.7% from $69.374M for the nine months ended September 30, 2025 |
| Non-current Deferred Revenue | $19.957M | Decreased from $23.300M at December 31, 2024, suggesting fewer long-term collaboration payments |
| Total Assets | $93.510M | Decreased by 31.4% from $136.388M at December 31, 2024 |
| Net Loss (Q2 2025) | $25.3M | Increased from $18.7M in Q2 2024, indicating widening losses. |
| Net Loss (YTD 2025) | $50.1M | Increased from $37.2M in YTD 2024, showing accelerating cash burn. |
| Increase in Q2 Net Loss | 35% | Percentage increase in net loss from Q2 2024 to Q2 2025. |
| Filing Date | 20250415 | Date the definitive proxy statement was filed. |
| Meeting Date | 20250528 | Date of the annual meeting of stockholders. |
Forward-Looking Statements
- {"claim":"Capital World Investors will continue to be a significant institutional holder of Precision BioSciences shares.","entity":"Capital World Investors","targetDate":"Next 12 months","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Precision Biosciences Inc (DTIL)?
Precision Biosciences Inc has 43 recent SEC filings from Jan 2024 to Apr 2026, including 21 8-K, 5 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DTIL filings?
Across 43 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Precision Biosciences Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Precision Biosciences Inc (DTIL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Precision Biosciences Inc?
Key financial highlights from Precision Biosciences Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DTIL?
The investment thesis for DTIL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Precision Biosciences Inc?
Key executives identified across Precision Biosciences Inc's filings include Durham, Dr. Michael A. Caligiuri, Dr. Sarah E. Michaels.
What are the main risk factors for Precision Biosciences Inc stock?
Of DTIL's 26 assessed filings, 2 were flagged high-risk, 16 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Precision Biosciences Inc?
Recent forward-looking statements from Precision Biosciences Inc include guidance on {"claim":"Capital World Investors will continue to be a significant institutional holder of Precision BioSciences shares.